Sección de Neuropediatría, Servicio de Pediatría, Hospital Virgen de la Arrixaca, Murcia, España.
Unidad de Cuidados Intensivos Pediátricos, Servicio de Pediatría, Hospital Virgen de la Arrixaca, Murcia, España.
Neurologia. 2017 Nov-Dec;32(9):616-622. doi: 10.1016/j.nrl.2016.04.008. Epub 2016 Jun 21.
ROHHAD syndrome (rapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation) is a rare and complex disease, presenting in previously healthy children at the age of 2-4 years. Up to 40% of cases are associated with neural crest tumours.
We present the case of a 2-year-old girl with symptoms of rapidly progressing obesity, who a few months later developed hypothalamic dysfunction with severe electrolyte imbalance, behaviour disorder, hypoventilation, and severe autonomic dysregulation, among other symptoms. Although the pathophysiology of this syndrome remains unclear, an autoimmune hypothesis has been proposed for ROHHAD. Therefore, after obtaining a limited response to intravenous immunoglobulins, we decided to test the response to a high dose cyclophosphamide (low dose was not effective either). Unfortunately our patient experienced many severe complications (among them central pontine myelinolysis, from which the patient recovered, and failure to wean from the ventilator requiring tracheostomy and long term ventilation) that required a prolonged ICU stay. Although her behaviour improved, our patient unfortunately died suddenly at home at the age of 5 due to respiratory pathology.
ROHHAD syndrome is a rare and little-known disease which requires a multidisciplinary approach because it involves complex symptoms and multiple organ system involvement. Alveolar hypoventilation should be identified early and appropriate treatment should be started promptly for the best possible outcome. Immunomodulatory treatment with immunoglobulins, cyclophosphamide, or rituximab has previously resulted in symptom improvement in some cases. Because of the low incidence of the syndrome, multi-centre studies must be carried out in order to gather more accurate information about ROHHAD pathophysiology and design an appropriate therapeutic approach.
ROHHAD 综合征(快速进展性肥胖伴下丘脑失调、通气不足和自主神经功能障碍)是一种罕见且复杂的疾病,发生于 2-4 岁的既往健康儿童。多达 40%的病例与神经嵴肿瘤有关。
我们报告了一例 2 岁女孩,其症状为迅速进展性肥胖,数月后出现下丘脑功能障碍,伴有严重电解质失衡、行为障碍、通气不足和严重自主神经功能障碍等症状。尽管该综合征的病理生理学仍不清楚,但已提出 ROHHAD 的自身免疫假说。因此,在静脉注射免疫球蛋白获得有限反应后,我们决定测试大剂量环磷酰胺的反应(小剂量也没有效果)。不幸的是,我们的患者经历了许多严重并发症(其中包括桥脑中央髓鞘溶解症,患者从中恢复,以及无法脱离呼吸机,需要气管切开和长期通气),导致 ICU 住院时间延长。尽管她的行为有所改善,但我们的患者不幸在 5 岁时因呼吸病理学在家中突然去世。
ROHHAD 综合征是一种罕见且鲜为人知的疾病,需要多学科方法,因为它涉及复杂的症状和多个器官系统受累。肺泡通气不足应早期识别,并应及时开始适当的治疗,以获得最佳结果。免疫球蛋白、环磷酰胺或利妥昔单抗的免疫调节治疗以前在某些情况下已导致症状改善。由于该综合征的发病率低,必须开展多中心研究,以收集关于 ROHHAD 病理生理学的更准确信息,并设计适当的治疗方法。